Zoetis Inc. (NYSE:ZTS) Shares Acquired by Blue Zone Wealth Advisors LLC

Blue Zone Wealth Advisors LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,137 shares of the company’s stock after purchasing an additional 1,513 shares during the period. Zoetis accounts for about 1.5% of Blue Zone Wealth Advisors LLC’s holdings, making the stock its 29th biggest holding. Blue Zone Wealth Advisors LLC’s holdings in Zoetis were worth $4,911,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Webster Bank N. A. boosted its position in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares during the period. Neo Ivy Capital Management purchased a new position in Zoetis in the 4th quarter worth approximately $40,000. Quarry LP boosted its holdings in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the period. LRI Investments LLC acquired a new stake in Zoetis in the first quarter valued at approximately $43,000. Finally, Ables Iannone Moore & Associates Inc. purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $51,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZTS has been the subject of several analyst reports. BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler boosted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, Stifel Nicolaus increased their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus target price of $220.38.

Zoetis Stock Performance

Shares of Zoetis stock opened at $187.28 on Tuesday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm’s 50-day simple moving average is $187.30 and its 200-day simple moving average is $175.50. The firm has a market cap of $84.85 billion, a PE ratio of 36.08, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.41 earnings per share. Equities analysts forecast that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.